Patient P-02666

Synthetic patientMETA-24 · Day 102 · 35–44 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

92%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 75 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 91 ME-01 recommended — Monitoring Escalation ME-01
Day 92 Patient accepted — Started ME-01 in the companion
Day 95 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 75.

Primary contributors, last 14 days

Treatment adherence-12
Toxicity+12
Inflammatory activity+8
Nutritional resilience-2

What helped?

Monitoring Escalation ME-01Day 91
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
87% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

20 min

worsening · -3.1 vs previous 14 d

Sleep duration

Wearable

5.5 h

worsening · -0.4 vs previous 14 d

Energy level

Daily log

2/10

worsening · -1.3 vs previous 14 d

Steps

Wearable

2,023

worsening · -512 vs previous 14 d

GI burden

Companion

72.3/100

worsening · +6.9 vs previous 14 d

Adherence

Companion

67.7 %

worsening · -15.3 vs previous 14 d

Sleep quality

Wearable

17.3/100

worsening · -7.1 vs previous 14 d

Glucose, CGM daily mean

CGM

161 mg/dL

worsening · +7.7 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 28 from the failing basin, 75 from restoration.

Would help

GI-04 GI Support Protocol
75% improved among 64 similar · onset 8 d · confidence 97%
NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 75%
SC-12 Supportive Compound
72% improved among 25 similar · onset 6 d · confidence 75%
More protein
GI -5.3 next day on high-intake days · n 19

Would not help

Keep histamine low
GI +5.4 next day on high-intake days · n 19
Keep alcohol low
GI +5.2 next day on high-intake days · n 26

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+5.4detractor · 95%
Protein
-5.3supporter · 95%
Alcohol
+5.2detractor · 95%
Caffeine
-2.2no signal · 52%
Dietary fat load
-1no signal · 25%
Simple carbohydrates
+0.9no signal · 17%
Ultra-processed food
+0.7no signal · 17%
Insoluble fibre
-0.2no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 72 and rising
- WearableSleep 5.5 h, below personal baseline
Autonomic recovery ↓65
- WearableResting HR 82 bpm
- Wearable2,023 steps/day
- WearableShort sleep window
Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 66
- WearableHRV 30 ms, trending down
Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑20
- BloodToxicity index 52

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Intermediate metabolizer
Expected exposure

Microbiome

Shannon diversity 3.2 · butyrate capacity 46/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 31 ms
Sleep: 6.0 h
Steps: 3,398
Resting HR: 82 bpm

Daily log: GI score 72, nutritional resilience 33, adherence 68.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02318	44%	S14	GI-04	no change	62
P-02165	41%	S14	ME-01	improved	59
P-02508	38%	S14	ME-01	improved	51
P-02060	37%	S14	GI-04	improved	54
P-02409	37%	S01	SC-12	no change	54
P-02595	37%	S02	—	—	53
P-02236	36%	S14	GI-04	improved	45
P-02575	36%	S14	ME-01	improved	73
P-02444	35%	S07	—	—	59
P-02078	34%	S04	—	—	56
P-02381	34%	S14	SC-12	improved	52
P-02046	33%	S10	—	—	55